| Ticker Symbol: | VRUS |
|---|---|
| Exchange: | NASD |
| Contact Info: | |
| CEO/President: | |
| Industry: | Medical - Drugs / Standard Industry Code: |
| Description: | PHARMASSET INC is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, hepatitis C virusand human immunodeficiency virus. |
| Shares Outstanding: | 21,590 (000) | Market Value: | 363,550 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 46.84% | Number of Inst.Shareholders: | 14.50% |
| Last Quarter Sales: | 0.46 ($Mil.) | Last Quarter Net Income: | -15.03 ($Mil.) |
| Last Quarter EPS: | -0.69 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -2.23 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |